MedTrace Logo

Use of Somatropin in Turner Syndrome

NCT01518036 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2017-02-28

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this trial is to study the dose-response relationship and effect of somatropin (Norditropin®) on final height in girls with Turner Syndrome.

Conditions

  • Genetic Disorder
  • Turner Syndrome

Interventions

DRUG

somatropin

2.9 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached

DRUG

somatropin

4.3 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
11 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1987-09-14
Primary Completion
2004-04-11
Completion
2004-04-11

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01518036 on ClinicalTrials.gov